INSMInsmed, Inc.

CSNasdaq (XNAS)·USD

Identity

Security key: 17122
Ticker: INSM
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2000-06-01
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: INSM

Detail

Enriched 2026-08-14 20:47

Market cap: $28,887,505,216.84
Shares outstanding (class): 218,381,503
Shares outstanding (weighted): 218,381,503
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 1,664
Location: BRIDGEWATER, NJ
Homepage: https://www.insmed.com
Description: Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Market cap and share counts drift.

Funds holding this security

380 funds · 389 positions · $10.17B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
JPMorgan Large Cap Growth Fund JPMorgan Trust II	—	$1.74B	1.62%	10,633,939 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$1.12B	0.06%	6,850,260 NS	FIGI
Invesco QQQ Trust, Series 1 Invesco QQQ Trust, Series 1	QQQ	$742.51M	0.20%	4,540,817 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$406.36M	0.25%	2,485,062 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$389.31M	0.48%	2,380,795 NS	FIGI
VANGUARD MID-CAP INDEX FUND VANGUARD INDEX FUNDS	VO	$380.61M	0.19%	2,327,576 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$259.65M	3.20%	1,587,887 NS	FIGI
JPMorgan Mid Cap Growth Fund JPMorgan Trust II	—	$253.44M	2.22%	1,549,913 NS	FIGI
VANGUARD GROWTH INDEX FUND VANGUARD INDEX FUNDS	VUG	$249.65M	0.08%	1,526,740 NS	FIGI
JPMorgan Growth Advantage Fund J.P. Morgan Mutual Fund Investment Trust	—	$246.02M	1.22%	1,504,495 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$227.37M	0.59%	1,390,446 NS	FIGI
iShares Russell Mid-Cap Growth ETF iShares Trust	IWP	$215.35M	1.15%	1,316,972 NS	FIGI
Fidelity Contrafund Fidelity Contrafund	—	$148.53M	0.09%	908,349 NS	FIGI
SMALLCAP World Fund Inc SMALLCAP World Fund Inc	—	$139.98M	0.17%	856,070 NS	FIGI
VANGUARD MID-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VOT	$134.05M	0.46%	819,756 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERINSM
FIGI_COMPOSITEBBG000BWM5P3
FIGI_SHARE_CLASSBBG001S9SKW7
CIK0001104506
ISINUS4576693075
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Insmed is a biopharmaceutical company developing therapies, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.